MiRDA-C 研究结直肠癌患者的微小残留病评估
结直肠癌最小残留病评估 (MiRDA-C)
This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.
研究概览
地位
地位
条件
条件
干预/治疗
干预/治疗
详细说明
PRIMARY OBJECTIVES:
I. Demonstrate ability to monitor cancer-specific deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and proteomic alterations from plasma.
II. Improve detection of recurrences post completion of curative therapies through monitoring of plasma cancer-specific DNA, RNA and proteomic alterations.
SECONDARY OBJECTIVES:
I. Qualitative and quantitative changes in cancer-specific plasma alterations during neoadjuvant, adjuvant therapies and surveillance.
II. Disease free survival (DFS) of patients with detectable cancer-specific plasma alterations.
III. Overall survival (OS) of patients with detectable cancer-specific plasma alterations.
EXPLORATORY OBJECTIVES:
I. Optimal combination of cancer-specific plasma DNA, RNA and / or proteomic alterations for early detection of recurrences.
II. Sensitivity, specificity, positive predictive and negative predictive values of cancer-specific plasma alterations in detecting recurrences.
III. Correlation between cancer-specific alterations in plasma and tissue and either with outcomes including DFS & OS.
IV. Nature and frequency of detection of incidental non-colorectal cancer related DNA, RNA and / or proteomic alterations.
OUTLINE:
Patients undergo collection of blood samples at baseline, during each neoadjuvant therapy treatment, prior to surgical resection, and up to 4 times per year for up to 5 years. Patients also undergo collection of tissue sample at time of surgical resection. Patients' medical records may also be reviewed.
研究类型
研究类型
注册 (估计的)
注册
联系人和位置
学习联系方式
学习联系方式
- 姓名:Arvind Dasari
- 电话号码:(713) 792-2828
- 邮箱:adasari@mdanderson.org
学习地点
-
-
Arizona
-
Gilbert、Arizona、美国、85234
- 终止
- Banner - MD Anderson Cancer Center
-
-
Florida
-
Jacksonville、Florida、美国、32207
- 终止
- Baptist- MD Anderson Cancer Center
-
-
Hawaii
-
Honolulu、Hawaii、美国、96813
- 终止
- The Queen's Medical Center
-
-
Idaho
-
Boise、Idaho、美国、83712
- 终止
- St. Luke's Cancer Institute
-
-
New Jersey
-
Camden、New Jersey、美国、08103
- 终止
- Cooper Hospital UNIV MED CTR.
-
-
Texas
-
Dallas、Texas、美国、75390
- 终止
- UT Southwestern/Simmons Cancer Center-Dallas
-
Houston、Texas、美国、77030
- 招聘中
- M D Anderson Cancer Center
-
接触:
- Arvind Dasari
- 电话号码:713-792-2828
- 邮箱:adasari@mdanderson.org
-
首席研究员:
- Arvind Dasari
-
Houston、Texas、美国、77030
- 终止
- Houston Methodist Cancer Center
-
San Antonio、Texas、美国、78229
- 终止
- UT Health San Antonio MD Anderson Cancer Center
-
Temple、Texas、美国、76508
- 终止
- Baylor Scott & White Research Institute
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients with colorectal cancer at MD Anderson Cancer Center.
描述
Inclusion Criteria:
- Age ≥ 18 years.
- Histological/cytological confirmation of colorectal adenocarcinoma.
- Patients with any stage colorectal adenocarcinoma deemed potentially eligible for curative intent treatment. Patients with stages II-IV colorectal cancer post-R0 resection may also be enrolled onto the protocol any time before or up to 3 months post-surgery and prior to initiating adjuvant therapy.
- Ability to understand and the willingness to sign a written informed consent document.
- Willing to pursue standard of care surveillance post completion of curative therapies.
- Willing to provide blood samples for correlative research.
Exclusion Criteria:
- Known active malignancies other than colorectal adenocarcinoma that may interfere with detection and / or interpretation of circulating plasma markers. Patients with known clonal hematopoiesis of indeterminate potential are eligible.
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
团体/队列数
队列和干预
团体/队列团体/队列 |
干预/治疗干预/治疗 |
|---|---|
|
Ancillary-correlative (biospecimen collection)
Patients undergo collection of blood samples at baseline, during each neoadjuvant therapy treatment, prior to surgical resection, and up to 4 times per year for up to 5 years. Patients also undergo collection of tissue sample at time of surgical resection. Patients medical records may also be reviewed. |
Review of medical records Undergo collection of blood and tissue samples |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Analysis of deoxyribonucleic (DNA), ribonucleic acid (RNA), and proteomic alterations from plasma
大体时间:Up to 5 years
|
To detect circulating tumor DNA (ctDNA) in plasma samples from patients with colorectal cancer (CRC) who have completed curative therapies (i.e. minimal residual disease) towards predicting recurrence earlier than the current standard of care utilizing the CRC23 assay and the LUNAR assay from Guardant Health technology. |
Up to 5 years
|
|
Detection of recurrences post completion of curative therapies
大体时间:Up to 5 years
|
To detect ctDNA in plasma samples from patients with CRC who have completed curative therapies (i.e. minimal residual disease) towards predicting recurrence earlier than the current standard of care utilizing the CRC23 assay and the LUNAR assay from Guardant Health technology. |
Up to 5 years
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
无病生存 (DFS)
大体时间:长达 5 年
|
长达 5 年
|
|
|
总生存期(OS)
大体时间:长达 5 年
|
长达 5 年
|
|
|
Changes in cancer-specific plasma alterations during neoadjuvant, adjuvant therapies and surveillance
大体时间:Baseline up to 5 years
|
Will assess the association between changes in circulating molecules and response in patients undergoing neoadjuvant therapy by linear or logistic regression models |
Baseline up to 5 years
|
其他结果措施
其他结果措施
结果测量 |
大体时间 |
|---|---|
|
癌症特异性血浆 DNA、RNA 和/或蛋白质组学改变的最佳组合,用于早期检测复发
大体时间:长达 5 年
|
长达 5 年
|
|
癌症特异性血浆改变检测复发的敏感性、特异性、阳性预测值和阴性预测值
大体时间:长达 5 年
|
长达 5 年
|
|
血浆和组织中癌症特异性改变与包括 DFS 和 OS 在内的结果之间的相关性
大体时间:长达 5 年
|
长达 5 年
|
|
偶发的非结直肠癌相关 DNA、RNA 和/或蛋白质组改变的性质和检测频率
大体时间:长达 5 年
|
长达 5 年
|
合作者和调查者
调查人员
调查人员
- 首席研究员:Arvind Dasari、M.D. Anderson Cancer Center
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他研究编号
其他研究编号
- PA18-1171
- PA18-1171 (其他标识符:M D Anderson Cancer Center)
- NCI-2020-10034 (注册表标识符:CTRP (Clinical Trial Reporting Program))
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.